(NASDAQ: MAZE) Maze Therapeutics's forecast annual revenue growth rate of -28.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.21%.
Maze Therapeutics's revenue in 2026 is $20,000,000.On average, 13 Wall Street analysts forecast MAZE's revenue for 2026 to be $1,133,203,027, with the lowest MAZE revenue forecast at $1,088,763,693, and the highest MAZE revenue forecast at $1,166,532,528. On average, 13 Wall Street analysts forecast MAZE's revenue for 2027 to be $509,941,362, with the lowest MAZE revenue forecast at $0, and the highest MAZE revenue forecast at $3,499,597,584.
In 2028, MAZE is forecast to generate $528,494,784 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $2,916,331,320.